MAP3K11 and breast carcinoma: In light of these data, we first tested whether pharmacologic inhibition of MLK3 with a novel, brain penetrant, MLK3 inhibitor, URMC099 [16], [17], blocks the in vitro migratory activity of human breast cancer cells.